
The Swizz company Roche and its subsidiary Genentech now have the results of a phase III trial with the candidate drug trastuzumab emtansine.
The study tests the effect of the candidate on the aggressive type of breast cancer known as HER2-positive metastatic breast cancer (MBC). Data shows that the risk of dying was reduced by 32 % for patients treated with trastuzumab emtansine, compared with those that received standard treatment in the form of a combination of the drugs lapatinib and xeloda.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app